US Pharm. 2010;35(11)(Oncology suppl):17.
Rexahn Pharmaceuticals, Inc., announced new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal of Medicinal Chemistry. In a clinical study, various substituted 3-aryl-1-isoquinolinamine derivatives were shown to have excellent cytotoxicity against breast, prostate, colon, ovary, kidney, pancreas, glioblastoma, and melanoma cancer cells. These derivatives were synthesized and analyzed through the constructed quantitative structure-activity relationship (QSAR) model, used to find lead compounds, and in in vitro cell studies.
"In this second published study, we further establish that isoquinolinamine derivatives, such as our anticancer compound RX-8243—a new chemical entity—are potent anticancer compounds that have the potential to be developed into chemotherapeutic agents," said Rick Soni, president of Rexahn.
In September, Rexahn announced the release of new clinical data in Bioorganic & Medicinal Chemistry Letters demonstrating that RX-8243 significantly inhibits human cancer cell growth.
